NCT03861403 - A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions

Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast CancerAdvanced Metastatic Castration-Resistant Prostate CancerAdvanced Platinum-Resistant Ovarian Cancer

Interventions

DRUG

TRX518

Administered by IV infusion

DRUG

Cyclophosphamide

Administered by IV infusion

DRUG

Avelumab

Administered by IV infusion

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

22903

University of Virginia, Charlottesville

44195

Cleveland Clinic, Cleveland

47905

Horizon Oncology Research, Lafayette